Literature DB >> 7585513

Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control.

J Lukas1, L Aagaard, M Strauss, J Bartek.   

Abstract

The p16INK4/CDKN2, D-type cyclins, their partner cyclin-dependent kinases, and retinoblastoma protein constitute a G1 regulatory pathway commonly targeted in oncogenesis. We show that, unexpectedly, abnormalities of p16INK4/CDKN2 occur concomitantly in two-thirds of cancer cell lines harboring aberrations of cyclin D1. Gene and protein transfer experiments demonstrated that concurrent alterations of cyclin D1 and p16 levels cooperate to (de)regulate G1 control in diploid fibroblasts, and that both events influence growth of retinoblastoma (RB)-positive, but not RB-deficient cancer cells. These results show that biological consequences of deregulating individual components along the pathway are unequal, reflecting their hierarchical roles in the G1 checkpoint control. Whereas RB defects eliminate the checkpoint completely, aberrations of the upstream components, such as cyclin D1 and p16INK4/CDKN2, can cooperate in multistep tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585513

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.

Authors:  M Sánchez-Beato; A I Sáez; I C Navas; P Algara; M Sol Mateo; R Villuendas; F Camacho; A Sánchez-Aguilera; E Sánchez; M A Piris
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

3.  Dysregulation of the Rb pathway in recurrent pleomorphic adenoma of the salivary glands.

Authors:  Ana Amélia de Souza; Albina Altemani; Fabricio Passador-Santos; Cecilia Pedroso Turssi; Ney Soares de Araujo; Vera Cavalcanti de Araújo; Andresa Borges Soares
Journal:  Virchows Arch       Date:  2015-07-09       Impact factor: 4.064

4.  Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.

Authors:  Kathleen M Woods Ignatoski; Michele L Dziubinski; Cheryl Ammerman; Stephen P Ethier
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

5.  Transcriptional repression by RB-E2F and regulation of anchorage-independent survival.

Authors:  J T Yu; R G Foster; D C Dean
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

6.  Exogenous expression of p16INK4a is associated with decrease in telomerase activity.

Authors:  H Sawa; H Kamada; T A Ohshima; A Noguchi; N Itoh; K Saruta; M Hara; I Saito
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

7.  In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.

Authors:  Xu-ming Ji; Bing Ouyang; Heng Liu; Guo-wei Liu; Zhi-chun Wu; Hua-yun Yu; Chun-yan Wang; Zhong-xia Wang; Wen-ping Wang
Journal:  Chin J Integr Med       Date:  2011-12-03       Impact factor: 1.978

Review 8.  Cell cycle regulators and their abnormalities in breast cancer.

Authors:  P L Fernández; P Jares; M J Rey; E Campo; A Cardesa
Journal:  Mol Pathol       Date:  1998-12

9.  Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients.

Authors:  Zhi-jie Fu; Zhi-yong Ma; Qi-rong Wang; Da-peng Lei; Rong Wang; Chun-xi Liu; Xin-liang Pan
Journal:  Clin Exp Metastasis       Date:  2008-09-12       Impact factor: 5.150

10.  CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients.

Authors:  M K Sibin; Dhananjaya I Bhat; Ch Lavanya; M Jeru Manoj; S Aakershita; G K Chetan
Journal:  Tumour Biol       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.